Compare Ascendis Pharma A/S (ASND) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs J M Smucker Co — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while J M Smucker Co trades at $111.37 (market cap $11.93B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and J M Smucker Co pays a 3.94% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SJM | |
|---|---|---|
Market Cap | $17.74B | $11.93B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $117.05 |
52-Week Low | $163.32 | $89.53 |
Enterprise Value | $18.11B | $18.96B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SJM trades at $111.60, up 0.66% today, with technical indicators showing a bearish bias despite recent earnings beats. The company reported a net loss of $1.23 billion in 2025, though revenue grew to $8.73 billion. Analyst consensus is bullish with a $122.92 price target, but weak profitability metrics and high debt levels pose challenges. Recent news highlights mixed sentiment, with some outlets praising growth potential while others caution on sales pressure.
The outlook hinges on margin recovery in coffee and growth in Uncrustables, but fiscal 2027 sales guidance of a 3-4% decline tempers optimism. Risks include competitive pressures and debt management, while the 4% dividend yield offers income support. Upside depends on execution against muted growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
